Pamela McMahon, PhD is a Research Scientist in the Department of Population Medicine at the Harvard Pilgrim Health Care Institute. She serves as the Project Director of the Precision Medicine Prevention and Treatment (PreEMPT) Model, designed to simulate the health and economic outcomes accruing to newborns undergoing genomic screening for an assortment of heritable conditions. She is an outcomes researcher with expertise in the use of modeling to integrate disparate data to inform healthcare policies.
Her prior research encompassed simulation-based evaluations of lung and breast cancer screening and lung and prostate cancer treatments, as well as cost analyses of interventions (e.g., palliative care, diagnostic imaging) and methods in statistics and optimization. She was Associate Director of the MGH Institute for Technology Assessment and the Principal Investigator of the Coordinating Center for the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET). The Lung Cancer Policy Model, developed as part of her doctoral dissertation, was one of five CISNET lung models that completed extensive evaluations to inform the U.S. Preventive Services Task Force’s 2013 guidelines for lung cancer screening. She later contributed statistical and modeling expertise to a range of industry clients as a Managing Scientist at a scientific consulting firm.
Dr. McMahon completed her PhD in Health Policy/Decision Science at Harvard and her BS in Biology at Cornell University.
(617) 867 - 4580